Breakthrough cancer treatment goes on trial in china
NCT ID NCT06416696
Summary
This study is testing whether adding a more affordable immunotherapy drug called toripalimab to standard chemoradiation treatment can better control high-risk cervical cancer. It will involve 57 patients with advanced cervical cancer who have not received prior treatment. The main goal is to see if this combination improves two-year survival without the cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.